Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

1. Insulins (all types): risk of cutaneous amyloidosis at injection site

Insulins (all types): risk of cutaneous amyloidosis at injection site Insulins (all types): risk of cutaneous amyloidosis at injection site - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search National restrictions in England from 5 November Take action (...) now for new rules in 2021 Insulins (all types): risk of cutaneous amyloidosis at injection site Cutaneous amyloidosis at the injection site has been reported in patients using insulin and this may affect glycaemic control. Remind patients to rotate injection sites within the same body region. Published 23 September 2020 From: Therapeutic area: Contents Advice for healthcare professionals: injection of insulin (all types) can lead to deposits of amyloid protein under the skin (cutaneous amyloidosis

2020 MHRA Drug Safety Update

2. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis Full Text available with Trip Pro

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 29. doi: 10.1111/dom.14202. Online ahead of print. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Centre of Research Excellence in Translating Nutritional Science to Good Health, University

2020 EvidenceUpdates

3. Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Insulin glargin/Lixisenatid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 July 2020). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. Extract IQWiG Reports – Commission No. A20-38 Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A20-38 Version 1.0 Insulin glargine/lixisenatide (type 2 diabetes mellitus) 13 July 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Insulin glargine/lixisenatide (type 2

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes

t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes Medtech innovation briefing Published: 22 September 2020 www.nice.org.uk/guidance/mib227 pathways Summary Summary • The technology technology described in this briefing is the t:slim X2 insulin pump. It is used for managing blood glucose levels in type 1 diabetes. • The innovative aspects innovative aspects are using advanced algorithms (...) with a continuous glucose monitor to predict low glucose and suspend insulin delivery. The technology software, Control-IQ, can also adjust basal insulin and give correction doses. • The intended place in therapy place in therapy would be as an alternative to other sensor-augmented insulin pumps for people with type 1 diabetes. • The main points from the evidence main points from the evidence summarised in this briefing are from 6 studies (including 4 randomised controlled trials, 1 randomised crossover study

2020 National Institute for Health and Clinical Excellence - Advice

5. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. (Abstract)

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes.We conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial to investigate the efficacy and safety (...) of once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not previously received long-term insulin treatment and whose type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while taking metformin with or without a dipeptidyl peptidase 4 inhibitor. The primary end point was the change in glycated hemoglobin level from baseline to week 26. Safety end points, including episodes of hypoglycemia and insulin-related adverse events

2020 NEJM

6. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2

Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) Metab Actions . 2020 Jul 3. doi: 10.1111/dom.14127. Online ahead of print. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 , , , , , , , Affiliations Expand Affiliations 1 Endocrine and Metabolic Consultants, Rockville, Maryland, USA. 2 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 3 Diabetes Centers of America-Dallas

2020 EvidenceUpdates

7. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Full Text available with Trip Pro

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial - PubMed This site needs JavaScript to work properly (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 21;dc192316. doi: 10.2337/dc19-2316. Online ahead of print. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial , , , , , , , , Affiliations Expand Affiliations 1 Dallas Diabetes Research Center at Medical City

2020 EvidenceUpdates

8. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial Full Text available with Trip Pro

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial - PubMed This site needs JavaScript (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul;43(7):1512-1519. doi: 10.2337/dc19-1926. Epub 2020 May 19. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100

2020 EvidenceUpdates

9. Insulin aspart - diabetes

Insulin aspart - diabetes Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/242544/2020 EMEA/H/C/005033 Insulin aspart Sanofi (insulin aspart) An overview of Insulin aspart (...) Sanofi and why it is authorised in the EU What is Insulin aspart Sanofi and what is it used for? Insulin aspart Sanofi is a medicine used to control blood glucose (sugar) levels in patients from one year of age who have diabetes. Insulin aspart Sanofi is a ‘biosimilar medicine’. This means that Insulin aspart Sanofi is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Insulin aspart Sanofi is NovoRapid. For more

2020 European Medicines Agency - EPARs

10. A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience Full Text available with Trip Pro

A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience A Pragmatic Study of Mid-Mixture Insulin and Basal Insulin Treatment in Patients With Type 2 Diabetes Uncontrolled With Oral Antihyperglycaemic Medications: A Lesson From Real-World Experience - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 8. doi: 10.1111/dom.14052. Online ahead of print. A Pragmatic Study of Mid-Mixture Insulin and Basal Insulin Treatment in Patients With Type 2 Diabetes Uncontrolled With Oral Antihyperglycaemic Medications: A Lesson

2020 EvidenceUpdates

11. Concise Advice on Inpatient Diabetes during COVID-19 - Guidelines for managing DKA using subcutaneous insulin

Concise Advice on Inpatient Diabetes during COVID-19 - Guidelines for managing DKA using subcutaneous insulin Version 3.3 29/4/2020 Page 1 COncise adVice on Inpatient Diabetes (COVID:Diabetes): GUIDELINE FOR MANAGING DKA USING SUBCUTANEOUS INSULIN (where intravenous insulin infusion is not possible) NATIONAL INPATIENT DIABETES COVID-19 RESPONSE GROUP* o For use in Covid-19 suspected/positive people and those without Covid-19 disease when diagnosis of DKA has been confirmed (see ? COVID (...) Inpatient Network – COVID-19 • Designed by: Leicester Diabetes CentreVersion 3.3 29/4/2020 Page 2 BASAL INSULIN o ALWAYS START/CONTINUE LONG-ACTING INSULIN WHEN TREATING DKA › If using regular injectable long-acting insulin this should be continued › If not previously using basal insulin initiate a dose of 0.15* units/kg/day (involve the local diabetes team at the earliest opportunity) If using a personal insulin pump either: 1. Continue basal insulin rate via pump if person can safely manage

2020 Association of British Clinical Diabetologists

12. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) Full Text available with Trip Pro

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) - PubMed This site needs JavaScript to work (...) : Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Mar 24;dc192232. doi: 10.2337/dc19-2232. Online ahead of print. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin

2020 EvidenceUpdates

13. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial Full Text available with Trip Pro

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) : Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14043. Online ahead of print. Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Centre, Institute for Clinical

2020 EvidenceUpdates

14. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial Full Text available with Trip Pro

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial (...) : ( ) Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 15;dc192452. doi: 10.2337/dc19-2452. Online ahead of print. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2

2020 EvidenceUpdates

15. Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Full Text available with Trip Pro

Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial - PubMed This site needs JavaScript to work properly. Please enable it to take (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Mar 12. doi: 10.1111/dom.14028. Online ahead of print. Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial

2020 EvidenceUpdates

16. Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus

Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus 1 Published 13 April 2020 1 SMC2235 insulin glargine plus lixisenatide (Suliqua®), 100 units/mL plus 50 microgram/mL and 100 units/mL plus 33 micrograms/mL solution for subcutaneous injection in pre-filled pens Aventis Pharma Limited, trading as Sanofi 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission insulin glargine/lixisenatide (Suliqua ® ) is accepted for restricted use within NHSScotland. Indication under review: In combination with metformin for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal

2020 Scottish Medicines Consortium

17. Insulin Aspart (Fiasp)

Insulin Aspart (Fiasp) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical

2020 Health Canada - drugs and medical devices

18. Insulin pumps for people with Type 1 Diabetes

Insulin pumps for people with Type 1 Diabetes 1 Driving better decision-making in healthcare Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes Technology Guidance from the MOH Medical Technology Advisory Committee Published on 23 March 2020 Guidance recommendations The Ministry of Health Medical Technology Advisory Committee has recommended: ? Continuous subcutaneous insulin infusion therapy (CSII) and its consumables as a treatment option for adults and children (...) with type 1 diabetes mellitus: o who use multiple daily injections of insulin (MDI) to achieve target HbA1c but result in the person experiencing disabling hypoglycaemia, where disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life (QoL); or o who have unacceptably high HbA1c (i.e. at 8.5% or above) on MDI despite a high level of care, where

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

19. A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice Full Text available with Trip Pro

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N = 1012 (...) . Estimated treatment differences for insulin dose (-13.01 U) and body weight change (-1.57 kg) significantly favoured IDegLira. The hypoglycaemia rate was 44% lower with IDegLira versus IGlar U100. Safety results were similar. In a trial resembling clinical practice, more participants receiving IDegLira than IGlar U100 met treatment targets, supporting use of IDegLira as an initial injectable therapy for people with T2D uncontrolled on OADs and eligible for insulin initiation.© 2020 The Authors. Diabetes

2020 EvidenceUpdates

20. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins

Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions 2020 Feb 19 [Online ahead of print] Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins , , , , , , , , , , Affiliations Expand Affiliations 1 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver

2020 EvidenceUpdates